[go: up one dir, main page]

NO971494L - Liposomformulering til behandling av virussykdommer - Google Patents

Liposomformulering til behandling av virussykdommer

Info

Publication number
NO971494L
NO971494L NO971494A NO971494A NO971494L NO 971494 L NO971494 L NO 971494L NO 971494 A NO971494 A NO 971494A NO 971494 A NO971494 A NO 971494A NO 971494 L NO971494 L NO 971494L
Authority
NO
Norway
Prior art keywords
treatment
liposomes
viral diseases
formulations
hiv
Prior art date
Application number
NO971494A
Other languages
English (en)
Other versions
NO971494D0 (no
Inventor
Michel G Bergeron
Andre Desormeaux
Original Assignee
Michel G Bergeron
Andre Desormeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michel G Bergeron, Andre Desormeaux filed Critical Michel G Bergeron
Publication of NO971494D0 publication Critical patent/NO971494D0/no
Publication of NO971494L publication Critical patent/NO971494L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet en fremgangsmåte for behandling av virussykdommer som omfatter administrering av antivirale midler innkapslet i liposomer. Det er også tilveiebragt formuleringer av liposomer for behandling av virussykdommer og mer spesielt for behandling av infeksjoner forårsaket av virus, såsom human immunsviktvirus (HIV) og cytomegalovirus (CMV). Disse formuleringer av liposomer er sammensatt av spesifikke klasser av lipidkomponenter og inneholder et omsluttet legemiddel som er effektiv mot virussykdommen. Disse liposomale formuleringer av antivirale legemidler tillater høy cellulær penetrasjon i forskjellige cellelinjer, god in vitro antiviral virkningsgrad mot HIV- og CMV-repIikasjon, effektiv in vivo målretting av HIV-reservoarer og markert forbedring av legemidlets farmakokinetikk.
NO971494A 1994-10-03 1997-04-02 Liposomformulering til behandling av virussykdommer NO971494L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31673594A 1994-10-03 1994-10-03
PCT/CA1995/000561 WO1996010399A1 (en) 1994-10-03 1995-10-03 Liposome-formulations for treatment of viral diseases

Publications (2)

Publication Number Publication Date
NO971494D0 NO971494D0 (no) 1997-04-02
NO971494L true NO971494L (no) 1997-05-27

Family

ID=23230423

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971494A NO971494L (no) 1994-10-03 1997-04-02 Liposomformulering til behandling av virussykdommer

Country Status (15)

Country Link
US (1) US5773027A (no)
EP (1) EP0784470B1 (no)
JP (1) JPH10506396A (no)
CN (1) CN1165480A (no)
AT (1) ATE246920T1 (no)
AU (1) AU714043B2 (no)
BR (1) BR9509217A (no)
CA (1) CA2201631C (no)
DE (1) DE69531499T2 (no)
ES (1) ES2204964T3 (no)
MX (1) MX9702435A (no)
NO (1) NO971494L (no)
NZ (1) NZ293216A (no)
PT (1) PT784470E (no)
WO (1) WO1996010399A1 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357930B1 (en) 1999-05-03 2008-04-15 Infectio Recherche Inc. Methods and formulations for targeting infectious agents bearing host cell proteins

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605437D0 (en) * 1996-03-15 1996-05-15 Iaf Biochem Int Cytomegalovirus inhibiting compounds
US6207185B1 (en) 1996-03-22 2001-03-27 Bio-Sphere Technology Method for inducing a systemic immune response to an HIV antigen
US6015576A (en) * 1997-08-29 2000-01-18 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to an antigen
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
US6410328B1 (en) * 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
US20050118250A1 (en) * 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability
AU2002340670A1 (en) * 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention
US20130085146A1 (en) * 2003-01-14 2013-04-04 Rodney J.Y. Ho Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
WO2004064731A2 (en) * 2003-01-14 2004-08-05 University Of Washington Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
US8986731B2 (en) * 2003-08-26 2015-03-24 Biolitec Pharma Marketing Ltd Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
CN101861143B (zh) * 2007-11-15 2015-09-09 拜莱泰克制药市场有限公司 用于炎性疾病的光动力治疗的聚乙二醇化脂质体制剂
EP2224963A1 (en) * 2007-11-19 2010-09-08 CeramOptec GmbH Pegylated compounds for age-related macular degeneration
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
ES2708360T3 (es) 2013-12-20 2019-04-09 Hoffmann La Roche Compuestos que comprenden uno o más dominios hidrófobos y un dominio hidrófilo que comprende restos de PEG, útiles para unir células
WO2015091948A1 (en) 2013-12-20 2015-06-25 Roche Diagnostics Gmbh Method of immobilizing a cell on a support using compounds comprising a polyethylene glycol moiety
WO2015091953A1 (en) 2013-12-20 2015-06-25 Roche Diagnostics Gmbh Use of compounds comprising two or more hydrophobic domains and a hydrophilic domain comprising peg moieties for stabilization of a cell
RU2669773C1 (ru) * 2017-05-30 2018-10-16 Федеральное государственное бюджетное учреждение "3 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации Способ определения модуля скорости неманеврирующей аэродинамической цели по выборкам измерений дальности
WO2022042531A1 (zh) * 2020-08-24 2022-03-03 清华大学 超声波搭配微气泡辅助的气球导管系统及其血管扩张方法
EP4108251A1 (en) 2021-06-22 2022-12-28 Solmic Biotech GmbH Griffithsin for use in a method of preventing or treating infections with respiratory viruses
EP4306130A1 (en) 2022-07-11 2024-01-17 Solmic Biotech GmbH Inhalable formulation for use in the treatment of bacterial lung infections
CN117582409A (zh) * 2023-11-21 2024-02-23 山西浙大新材料与化工研究院 一种用于破坏病毒囊膜结构的pH响应相转变磺酸脂质体及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4416872A (en) * 1982-03-17 1983-11-22 The United States Of America As Represented By The Secretary Of The Army Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates
US5254539A (en) * 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
IL86009A (en) * 1987-04-10 1991-09-16 Us Health Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases
US4997761A (en) * 1987-10-06 1991-03-05 Houston Biotechnology Incorporated Phosphatidyl treatment of viral disease
ZA902710B (en) * 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357930B1 (en) 1999-05-03 2008-04-15 Infectio Recherche Inc. Methods and formulations for targeting infectious agents bearing host cell proteins

Also Published As

Publication number Publication date
CA2201631A1 (en) 1996-04-11
DE69531499T2 (de) 2004-06-24
NO971494D0 (no) 1997-04-02
NZ293216A (en) 1999-03-29
CN1165480A (zh) 1997-11-19
AU714043B2 (en) 1999-12-16
AU3560395A (en) 1996-04-26
MX9702435A (es) 1997-06-28
US5773027A (en) 1998-06-30
PT784470E (pt) 2003-12-31
ATE246920T1 (de) 2003-08-15
EP0784470B1 (en) 2003-08-13
JPH10506396A (ja) 1998-06-23
DE69531499D1 (de) 2003-09-18
CA2201631C (en) 2004-05-04
ES2204964T3 (es) 2004-05-01
EP0784470A1 (en) 1997-07-23
WO1996010399A1 (en) 1996-04-11
BR9509217A (pt) 1998-01-27

Similar Documents

Publication Publication Date Title
NO971494D0 (no) Liposomformulering til behandling av virussykdommer
DK0774959T3 (da) Liposomalt indgivelsessystem for biologisk aktive midler
JP3240330B2 (ja) コラン酸の塩を含有する医薬調合剤および化粧品調合剤
SE9703191L (sv) Läkemedel för förbättring av muskelfunktionsdurationen eller behandling av muskelstörningar eller -sjukdom
CA2258811A1 (en) Formulation for use in the prevention of pathogen induced diseases including hiv and hsv
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
ATE181319T1 (de) Kationische lipide für die intrazelluläre abgabe von biologisch aktiven molekülen
FI951600A7 (fi) Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine
RU94036668A (ru) Средство для лечения заболеваний полости рта
AU2003233921A1 (en) Atomizable liposomes and their use for the pulmonary administration of active substances
CA2091134A1 (en) Therapeutic agent for threatened abortion
WO1994027584A3 (en) Arylating medicaments
GEP20022751B (en) Aqueous Pharmaceutical Composition Comprising an Active Ingredient Which Is Highly Insoluble in Water
HUP9900945A2 (hu) Nukleozidanalógok herpes simplex vírus fertőzések kombinációs terápiájában
RU98111152A (ru) Применение активного вещества флупиртина или его фармакологически приемлемых солей в качестве лекарственного средства для профилактики и лечения заболеваний, ассоциированных с повреждением клеточной системы гемопоэза
SE9900177L (sv) Användning av en beredning innehållande myrsyra för framställning av ett läkemedel för behandling av vårtor, orsakade av Papillomavirus
EP1283040A4 (en) ORAL PREPARATIONS WITH PROLONGED RELEASE
Murphy New antiretroviral drugs part I: PIs
ATE301453T1 (de) Injizierbare arzneiformulierungen von partricin derivaten
HUP0100937A2 (hu) Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen
WO1998036778A8 (en) Sustained drug delivery and compositions useful therefor
RU95102712A (ru) Липосомный фармацевтический препарат и лечебно-профилактический крем на его основе
Mairdan et al. Efficacy of Liposomal Albendazole for the Treatment of E. multilocularis in Rats
IT1277609B1 (it) Apparecchiatura per l'inattivazione virale di hiv in emoderivati e per supporto a trattamenti terapeutici di affezioni virali da hiv

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application